Sunday , October 22 2017
Home / KEEP BUT DO NOT DISPLAY / Alerts / Diamyd Medical reports on results from its European Phase III study

Diamyd Medical reports on results from its European Phase III study

 

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed Type 1 diabetes patients.